Clinical Trial

Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 19, 2021 (before its estimated September 2022 completion). Its status may not reflect the trial's current state.
Summary
DRAGON III research, Neoadjuvant Chemotherapy (FLOT versus SOX) for Gastric Cancer, is an investigator initiated; phase 3, open label, multi-center randomized controlled study.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-05-08; most recent amendment 2021-07-15.
Trial Details
NCT Number NCT04384601
Lead Sponsor Ruijin Hospital
Conditions Gastric Cancer, Neoadjuvant Chemotherapy
Enrollment 246 participants
Start Date 2021-09
Primary Completion 2022-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2021-07-19